Rami Komrokji, MD

Articles

Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

July 13th 2023

Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.

Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Dr Komrokji on the Classification of Patients With Myelodysplastic Syndromes

June 26th 2023

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

Risk Stratification of MDS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Diagnosing Myelodysplastic Syndromes (MDS)

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Dr Komrokji on Ongoing Studies in Higher- and Lower-Risk MDS

June 21st 2023

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.

Emerging Therapies for Lower-Risk MDS

February 24th 2023

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.

Luspatercept in Lower-Risk MDS

February 24th 2023

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

First- and Second-Line Treatment Options in Lower-Risk MDS

February 24th 2023

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Closing Remarks on Advances and Future Directions in MF and MDS

February 15th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, offer closing remarks on recent advances in MF and MDS, and look towards the future of treatment.

Remaining Unmet Needs and Additional Ongoing Trials in MF

February 8th 2023

Dr Komrokji summarizes the remaining unmet needs in the treatment of MF, including suboptimal responses to JAK2 inhibitors, and comments on data from ongoing trials that may address these needs.

Myelofibrosis: Treatment Landscape and Recent Data Updates on JAK2 Inhibitors

February 8th 2023

A comprehensive review of the treatment landscape for myelofibrosis (MF) and recent ASCO and ASH data updates on JAK2 inhibitors.

Data on Emerging Therapies for Treatment of Higher-Risk MDS

February 1st 2023

Experts in hematology take a detailed look at new data on investigational therapies for higher-risk MDS, including the STIMULUS-MDS1 trial on sabatolimab.

Oral Hypomethylating Agents in MDS: Data Updates

February 1st 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, discuss trial updates on oral hypomethylating agents, including data on dosing, for treatment of lower-risk MDS.

Trial Updates on Low-Dose Lenalidomide and Luspatercept

January 25th 2023

An overview of updates from the Sintra-REV trial of low-dose lenalidomide, and data from COMMANDS, MEDALIST, and real-world studies on luspatercept.

IMerge: Updated Safety and Efficacy Data on Imetelstat for Lower-Risk MDS

January 25th 2023

Hematology experts highlight recent data updates from the IMerge trial on the telomerase inhibitor imetelstat, which is being studied for lower-risk MDS.

Tools for Risk Stratification and Prognosis in MDS

January 18th 2023

Uwe Platzbecker, MD introduces models commonly used to determine risk status and prognosis, and inform treatment decisions, for patients with MDS.